title: Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders.
abstract: M-proteins are monoclonal immunoglobulins or immunoglobulin fragments that aberrantly accumulate in the plasma. Hemodialysis (HD) patients with M-proteins may, under certain circumstances, also need therapeutic plasma exchange (TPE). We employed a protocol for tandem TPE/HD in patients with M-protein disorders. We followed the urea reduction ratio (URR), a measure of the efficiency of HD, to compare the effect of TPE on HD efficiency during tandem procedures versus the efficiency of HD performed as a stand-alone procedure in the same patients. Three men (J.M., R.T., M.M.) underwent 23, 80, and 25 tandem TPE/HD over 3, 17, and 7 months, respectively, almost all in the outpatient setting. Mean whole blood flow rate (in ml/min) was slower during hemodialysis alone than during TPE/HD for J.M. (289 +/- 24 vs. 332 +/- 22, P < 0.0001) and R.T. (310 +/- 20 vs. 367 +/- 15, P < 0.0001) but not for M.M. (395 +/- 65 vs. 404 +/- 62, P = 0.6844). URR was equivalent during hemodialysis alone and during TPE/HD for J.M. (54 +/- 4.2 vs. 58 +/- 1.4, P = 0.3333), R.T. (69 +/- 4.9 vs. 70 +/- 2.5, P = 0.9804), and M.M. (71 +/- 2.4 vs. 67 +/- 1.5, P = 0.1143). J.M.'s renal function recovered sufficiently to permit discontinuation of hemodialysis. R.T. experienced both subjective and objective improvement of his arthritic symptoms. M.M. achieved hemostatic control but ultimately died of amyloidosis. TPE/HD is feasible using disparate pieces of equipment when the therapeutic plasma exchange circuit is connected in parallel with the low-pressure side of the hemodialysis circuit. Our experience illustrates that therapeutic plasma exchange did not adversely impact hemodialysis when the two procedures were performed in tandem.
authors.affiliation: Transfusion Medicine Section, Department of Medicine, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA.
authors.forename: Aftab
authors.initials: A
authors.lastname: Mahmood
authors.forename: Donata
authors.initials: D
authors.lastname: Sodano
authors.forename: Anthony
authors.initials: A
authors.lastname: Dash
authors.forename: Robert
authors.initials: R
authors.lastname: Weinstein
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis; D001168:Arthritis; D001783:Blood Flow Velocity; D001798:Blood Proteins; D003131:Combined Modality Therapy; D006487:Hemostasis; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D010265:Paraproteinemias / Q000150:complications / Q000628:therapy*; D010951:Plasma Exchange; D006435:Renal Dialysis
chemical_list: D001798:Blood Proteins; D007136:Immunoglobulins; C009823:M-proteins (Myeloma)